Trametinib in Adults with Neurofibromatosis Type 1‐Related Symptomatic Plexiform Neurofibromas
We observed a positive effect of trametinib on tumor volume and significant pain reduction in adults with plexiform neurofibromas. However, adverse events are common and frequently led to early termination of treatment. ANN NEUROL 2026;99:73-83.
Authors
- Martin J. van den Bent (ORCID: https://orcid.org/0000-0001-5710-5127)
- Erik A.C. Wiemer (ORCID: https://orcid.org/0000-0002-0673-7236)
- D. Christine Noordhoek (ORCID: https://orcid.org/0009-0002-7534-1531)
- Pim J. French (ORCID: https://orcid.org/0000-0002-0668-9529)
- Walter Taal (ORCID: https://orcid.org/0000-0002-5530-7259)
- Olivier C. Manintveld (ORCID: https://orcid.org/0000-0002-2202-7314)
- Sarah A. van Dijk (ORCID: https://orcid.org/0009-0002-2851-4620)
- David F. Hanff (ORCID: https://orcid.org/0000-0003-2743-0214)
Institutions
- Erasmus MC (NL)
- Erasmus MC Cancer Institute (NL)
Publication Details
- Journal
- Annals of Neurology
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1002/ana.78010
- Citations
- 1
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Novartis Pharma